Medications most likely to be seen in primary care

Size: px
Start display at page:

Download "Medications most likely to be seen in primary care"

Transcription

1 Hazardous Medicines The majority of medicines are not classed as hazardous. The only medicinal products that are automatically deemed to be hazardous are cytotoxic and cytostatic medicines. There is no definitive list of such products the following table has been developed using the National Institute for Occupational Safety and Health (INOSH) in the United States and medicines that are classified in Chapter 8 (Malignant Disease and Immunosuppression) of the British National Formulary. This is meant as a guide to assist segregation of hazardous medicinal waste.

2 Medications most likely to be seen in primary care Drug name anastrozole 8 tablets breast azathiopine 8 tablets transplant chloramphenicol 5 eye drops antibiotic ciclosporin 8 (10) capsules transplant colchicine 10 tablets gout cyproterone acetate 8 tablets prostate, fertility diethylstilbestrol 8 tablets prostate and breast dutasteride 6 capsules reduction of prostate estropipate 6 tablets HRT estriol 6 tablets HRT estradiol 6 HRT ethinylestradiol 8 tablets oestrogen deficiency finasteride 6 tablets prostate fluorouracil 8 capsules gastro tumours breast liquid cream hydroxycarbamide 8 capsules leukaemia leflunomide 10 tablets rheumatoid arthritis medroxyprogestrone 8 tablets endometrial acetate methotrexate 8 oral leukaemia and Non-Hodgkin s liquid lymphoma 10 tablets rheumatoid arthritis misoprostol tablets abortion + GI disorders norethisterone 8 tablets HRT, contraception progesterone 6 liquid gel pessaries raloxifene 6 tablets postmenopausal osteoporosis tacrolimus 8 capsules immunosuppressant tamoxifen 8 tablets breast testosterone 6 capsules tablets liquid implant patches gel zidovudine 5 capsules HIV

3 Medications, sorted alphabetically Drug name aldesleukin 8 kidney alemtuzumab 8 liquid infusion leukaemia amsacrine 8 liquid infusion leukaemia anastrozole 8 tablets breast arsenic trioxide 8 liquid infusion azathiopine 8 tablets transplant basiliximab 8 renal transplants BCG Vaccine 8 powder bladder bevacizumab 8 liquid infusion colon bexarotene 8 capsules skin bicalutamide 8 tablets prostate bleomycin 8 leukaemia bortezomib 8 myeloma buserelin 8 liquid prostate nasal spray busulfan 8 liquid infusion leukaemia tablets capecitabine 8 tablets colon carboplatin 8 liquid infusion ovarian and lung carmustine 8 implant cetrorelix acetate 6 female infertility cetuximab 8 liquid infusion colon chlorambucil 8 tablets leukaemia chloramphenicol 5 capsules antibiotic eye drops chorionicgonadotrophin 6 female infertility choriogonadotropin alfa 6 liquid female infertility ciclosporin 8 (10) capsules transplant liquid oral ciclosporin liquid infusion cidofovir 5 liquid infusion AIDS cisplatin 8 liquid testicular, lung, cervical, bladder, head and neck, ovarian cladribine 8 liquid infusion leukaemia colchicine 10 tablets gout crisantaspase 8 leukaemia cyclophosphamide 8 tablets rheumatoid arthritis cyproterone acetate 8 tablets prostate, fertility cytarabine 8 liquid leukaemia dacarbazine 8 skin

4 Drug name daclizumab 8 liquid infusion renal transplants dactinomycin 8 paediatric s daunorubicin HCL 8 leukaemia diethylstilbestrol 8 tablets prostate and breast dinoprostone 7 pessaries induce labour liquid infusion tablets gel docetaxel 8 liquid infusion breast and lung doxorubicin 8 leukaemia dutasteride 6 capsules reduction of prostate epirubicin 8 breast erlotinib 8 tablets lung estropipate 6 tablets HRT estriol 6 tablets HRT estradiol 6 HRT estrmustine phosphate 8 capsules prostate sodium ethinylestradiol 8 tablets oestrogen deficiency etoposide 8 liquid infusion testicular, lung capsules exemestane 8 tablets breast finasteride 6 tablets prostate 8 tablets immunosuppressant fluorouracil 8 capsules gastro tumours breast liquid cream flutamide 8 tablets prostate fulvestrant 8 liquid breast ganciclovir 5 liquid infusion Infection ganirelix acetate 6 liquid female infertility gemcitabine 8 lung, bladder glatiramer 8 liquid multiple sclerosis goserelin 8 implant prostate and breast hydroxycarbamide 8 capsules leukaemia idarubicin 8 capsules breast and leukaemia ifosafamide 8 imatinib 8 tablets leukaemia interfernon alfa-2b 8 interfernon alfa-n1 8 interferon alfa-2a 8 liquid hep b and c

5 Drug name Interferon Beta 8 liquid multiple sclerosis irinotecan HCL 8 liquid infusion colon lanreotide 8 liquid endocrine tumours, palliative care leflunomide 10 tablets rheumatoid arthritis letrozole 8 tablets breast leuprorelin acetate 8 prostate lomustine 8 capsules Hodgkin s disease medroxyprogestrone 8 tablets endometrial acetate megestrol 8 tablets endometrial melphalan 8 tablets breast, ovarian, myeloma menotropins 6 female infertility mercaptopurine 8 tablets leukaemia methotrexate 8 oral leukaemia and Nonliquid Hodgkin s lymphoma 10 tablets rheumatoid arthritis mifepristone 7 tablets abortion 7 liquid infusion induce labour misoprostol tablets abortion + GI disorders mitomycin 8 gastro tumours breast mitotane 8 tablets adrenal gland tumours mitoxantrone HCL 8 liquid infusion breast, leukaemia mustine mycophenolate mofetil 8 tablets organ transplant liquid infusion liquid oral nafarelin 6 liquid nasal spray endometriosis norethisterone 8 tablets HRT, contraception, octreotide 8 liquid endocrine tumours, palliative care oxaliplatin 8 liquid infusion colon oxytocin 7 liquid labour inducing paclitaxel 8 liquid infusion ovarian pentamidine isethionate 5 liquid nebuliser 5 liquid drops antibiotic drops for eyes and ears pentostatin 8 leukaemia podophyllum 13 liquid solution removal of genital warts porfimer Sodium 8 lung procarbazine 8 capsules Hodgkin s disease progesterone 6 liquid gel pessaries raloxifene 6 tablets postmenopausal osteoporosis

6 Drug name raltitrexed 8 colon ribavirin 5 tablets bronchiolitis, hep C inhalation capsules Rituximab 8 liquid infusion Non-Hodgkin s lymphoma sirolimus 8 tablets renal transplants syntometrine 7 liquid reduced bleeding after labour tacrolimus 8 capsules immunosuppressant liquid infusion tamoxifen 8 tablets breast tegafur with uracil 8 capsules colon temoporfin 8 liquid head and neck temozolomide 8 capsules testosterone 6 capsules tablets liquid implant patches gel thalidomide 8 thiotepa 8 bladder tioguanine 8 tablets leukaemia topotecan 8 infusion ovarian toremifene citrate 8 tablets breast Trastuzumab 8 breast treosulfan 8 capsules ovarian ovarian tretinoin 8 capsules leukaemia triptorelin 8 prostate, endometriosis valganciclovir 5 tablets AIDS vinblastine sulfate 8 liquid leukaemia vindesine 8 leukaemia vinorelbine tartrate 8 liquid infusion breast capsules zidovudine 5 capsules HIV

THE HAZARDOUS WASTE (ENGLAND AND WALES) REGULATIONS 2005

THE HAZARDOUS WASTE (ENGLAND AND WALES) REGULATIONS 2005 THE HAZARDOUS WASTE (ENGLAND AND WALES) REGULATIONS 2005 Interim Guidance for the NHS Hospital Sector for England and Wales and Information for Scotland Additional paper copies may be requested by contacting:

More information

GROUP 1 CARCINOGEN, CHEMOTHERAPY WASTE & OTHER HAZARDOUS DRUG DISPOSAL NAME APPROVAL DATE EFFECTIVE DATE REVISION RENEE MICHEL 05/01/11 0

GROUP 1 CARCINOGEN, CHEMOTHERAPY WASTE & OTHER HAZARDOUS DRUG DISPOSAL NAME APPROVAL DATE EFFECTIVE DATE REVISION RENEE MICHEL 05/01/11 0 GROUP 1 CARCINOGEN, CHEMOTHERAPY WASTE & OTHER HAZARDOUS DRUG DISPOSAL NAME APPROVAL DATE EFFECTIVE DATE REVISION RENEE MICHEL 05/01/11 0 INTRODUCTION Prior to commencing work involving carcinogens, chemotherapeutics

More information

Waste Management Policy

Waste Management Policy Sharepoint Location Non-clinical Policies and Guidelines Sharepoint Index Directory 3.0 Corporate Sub Area 3.2 Trustwide Management Key words (for search purposes) Waste, Hazardous, Sharps, Household Central

More information

SOUTH CENTRAL AMBULANCE SERVICE NHS FOUNDATION TRUST CORPORATE POLICY & PROCEDURE. No EPP20 WASTE MANAGEMENT. November 2015

SOUTH CENTRAL AMBULANCE SERVICE NHS FOUNDATION TRUST CORPORATE POLICY & PROCEDURE. No EPP20 WASTE MANAGEMENT. November 2015 SOUTH CENTRAL AMBULANCE SERVICE NHS FOUNDATION TRUST CORPORATE POLICY & PROCEDURE No EPP20 WASTE MANAGEMENT November 2015 DOCUMENT INFORMATION Author: Mike Kerrigan Head of Estates Consultation & Approval:

More information

Hydration, IV Infusions, Injections and Vaccine Charge Process

Hydration, IV Infusions, Injections and Vaccine Charge Process There are a number of items to be considered when billing for the Nursing service to perform drug therapy, the charge process is divided into three specific groups of codes and processes. 1. Hydration

More information

MOH Policy for dispensing NEOPLASTIC DISEASES DRUGS

MOH Policy for dispensing NEOPLASTIC DISEASES DRUGS MOH Policy for dispensing NEOPLASTIC DISEASES DRUGS All prescriptions for antineoplastic drugs must be accompanied by the MOH special form. All the attachments mentioned on this form shall be submitted

More information

Cost Differences in Cancer Care Across Settings

Cost Differences in Cancer Care Across Settings Cost Differences in Cancer Care Across Settings August 2013 THE MORAN COMPANY 1 Cost Differences in Cancer Care Across Settings In a prior memorandum, we presented evidence documenting the growing share

More information

NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2010

NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2010 NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2010 DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention National Institute for Occupational

More information

Waste management policy

Waste management policy Waste management policy Document Reference No. IPC006 Status Approved Version Number 3.1 Replacing/Superseded policy or v3.0 documents Number of Pages 26 Target audience/applicable to All Staff Author

More information

The Newcastle upon Tyne Hospitals NHS Foundation Trust. Handling, Segregation and Disposal of Cytostatic and Cytotoxic Waste

The Newcastle upon Tyne Hospitals NHS Foundation Trust. Handling, Segregation and Disposal of Cytostatic and Cytotoxic Waste The Newcastle upon Tyne Hospitals NHS Foundation Trust Handling, Segregation and Disposal of Cytostatic and Cytotoxic Waste Version.: 1.1 Effective From: 20 January 2016 Expiry Date: 20 January 2019 Date

More information

PHARMACY 1000.519 Effective Date Title: 10/12 HIGH-ALERT / HIGH-RISK / HAZARDOUS / LOOK ALIKE / SOUND ALIKE MEDICATIONS. Michele Goeb-Burkett 10/12

PHARMACY 1000.519 Effective Date Title: 10/12 HIGH-ALERT / HIGH-RISK / HAZARDOUS / LOOK ALIKE / SOUND ALIKE MEDICATIONS. Michele Goeb-Burkett 10/12 XXX DAYTONA XXX _OCEANSIDE XXX HEALTH CARE PARTNERS POLICY & PROCEDURE Department: Policy Number PHARMACY 1000.519 Effective Date Title: 10/12 HIGH-ALERT / HIGH-RISK / HAZARDOUS / LOOK ALIKE / SOUND ALIKE

More information

Principles on the Disposal of Waste Pharmaceuticals used within Community Health Services Version 3.1

Principles on the Disposal of Waste Pharmaceuticals used within Community Health Services Version 3.1 pecialist Pharmacy ervice Medicines Use and afety Principles on the Disposal of Waste Pharmaceuticals used within Community Health ervices Version 3.1 Introduction This document aims to define the principles

More information

for Extended Stability Parenteral Drugs Third Edition Caryn M. Bing, R.Ph., M.S., FASHP Editor

for Extended Stability Parenteral Drugs Third Edition Caryn M. Bing, R.Ph., M.S., FASHP Editor Extended Stability for Parenteral Drugs Third Edition Editor Caryn M. Bing, R.Ph., M.S., FASHP 1 American Society of Health-System Pharmacists Bethesda, Maryland Contents Preface Acknowledgments x/ Dedication

More information

8. Malignant disease and immunosuppression

8. Malignant disease and immunosuppression 1 8. Malignant disease and immunosuppression An ever increasing number of cytotoxic drugs and biological therapies - now referred to as Systemic anticancer therapy (SACT) - are used in the management of

More information

Oncologic drug Exposure Risks and Prevention Guidelines 19 June 2014

Oncologic drug Exposure Risks and Prevention Guidelines 19 June 2014 Oncologic drug Exposure Risks and Prevention Guidelines 19 June 2014 ส งค กคามซ งอาจเป นอ นตรายต อส ขภาพ HAZARD? HAZARD ส งค กคามซ งอาจเป นอ นตรายต อส ขภาพ ENCLOSURE Substitution ส งค กคามซ งอาจเป นอ นตรายต

More information

A guide to cancer types and chemotherapy medications

A guide to cancer types and chemotherapy medications A guide to cancer types and chemotherapy medications This guides lists words that mean cancer, cancer types and intravenous chemotherapy medications. If you have any questions, see page 10 for details

More information

HEALTH TECHNICAL MEMORANDUM

HEALTH TECHNICAL MEMORANDUM HEALTH TECHNICAL MEMORANDUM 07-06 Disposal of pharmaceutical waste in community pharmacies 2007 STATUS IN WALES APPLIES For queries on the status of this document contact info@whe.wales.nhs.uk or telephone

More information

Policies and Procedures. I.D. Number: 1044

Policies and Procedures. I.D. Number: 1044 Policies and Procedures Title: HAZARDOUS DRUGS (Non-Chemotherapy) ADMINISTRATION AND PRECAUTIONS I.D. Number: 1044 Authorization: [X] SHR Nursing Practice Committee Source: Nursing Date Revised: November

More information

MASCC/ESMO Antiemetic Guideline 2013

MASCC/ESMO Antiemetic Guideline 2013 MASCC/ESMO Antiemetic Guideline 2013 Multinational Association of Supportive Care in Cancer Organizing and Overall Meeting Chairs: Richard J. Gralla, MD Fausto Roila, MD Maurizio Tonato, MD Jørn Herrstedt,

More information

BREAST CANCER - METASTATIC & LOCALLY ADVANCED CHEMOTHERAPY REGIMENS Capecitabine. Capecitabine + Docetaxel. Capecitabine + Vinorelbine

BREAST CANCER - METASTATIC & LOCALLY ADVANCED CHEMOTHERAPY REGIMENS Capecitabine. Capecitabine + Docetaxel. Capecitabine + Vinorelbine Capecitabine Capecitabine 1000-1250mg/m 2 oral TWICE daily for 14 days Until disease progression Capecitabine + Docetaxel Capecitabine 750-1000mg/m 2 oral TWICE daily for 14 days Up to 6 cycles Capecitabine

More information

Acute Lymphoblastic Leukaemia

Acute Lymphoblastic Leukaemia 1 Royal Marsden and St Georges NHS Foundation Trusts PTC list of approved chemotherapy regimens 2015 Protocol Acute Lymphoblastic Leukaemia Acute Lymphoblastic Leukaemia and Lymphoblastic Lymphoma UKALL

More information

NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012

NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012 NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012 DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention National Institute for Occupational

More information

Synagis (Palivizumab)

Synagis (Palivizumab) Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization

More information

Effective Date: 6/3/14

Effective Date: 6/3/14 North Shore-Long Island Jewish Health System, Inc. Long Island Jewish Medical Center PATIENT CARE SERVICES POLICY TITLE: ORDERING, ADMINISTRATION AND DISPOSAL OF ORAL CHEMOTHERAPEUTIC AGENTS Prepared by:

More information

MEDICAL CENTER ADMINISTRATIVE POLICY AND PROCEDURES SCOPE KFH Hospital, City Section No.

MEDICAL CENTER ADMINISTRATIVE POLICY AND PROCEDURES SCOPE KFH Hospital, City Section No. of 22 I. Purpose To establish safe medication practices for High Alert medications to maximize the safety of the medication processes associated with these medications. II. Policy. High alert medications

More information

Guidelines for the Management of. Nausea and Vomiting in Cancer Patients

Guidelines for the Management of. Nausea and Vomiting in Cancer Patients Guidelines for the Management of Nausea and Vomiting in Cancer Patients Guidelines for the Management of Nausea and Vomiting in Cancer Patients Management of chemotherapy-induced nausea and vomiting includes

More information

Preventing and Treating Nausea and Vomiting Caused by Cancer Treatment

Preventing and Treating Nausea and Vomiting Caused by Cancer Treatment A Patient s Guide Preventing and Treating Nausea and Vomiting Caused by Cancer Treatment Recommendations of the American Society of Clinical Oncology The American Society of Clinical Oncology (ASCO) is

More information

ASWCS Policy for the Treatment of Extravasation Injury

ASWCS Policy for the Treatment of Extravasation Injury ASWCS Policy for the Treatment of Extravasation Injury Extravasation of Cytotoxic Drugs Introduction 1. The purpose of this policy is to inform practitioners of their responsibilities in relation to preventing

More information

National Pharmaceutical Pricing Authority 3 rd Floor, YMCA Cultural Centre 1 Jai Singh Road New Delhi 110001 File No. 23(01)2014/Div.

National Pharmaceutical Pricing Authority 3 rd Floor, YMCA Cultural Centre 1 Jai Singh Road New Delhi 110001 File No. 23(01)2014/Div. Dated 21 st November 2014 NPPA Invites Comments of Pharmaceutical Industry & Trade, Consumer Organisations, Public Health Experts and other Stakeholders on the Recommendations of Tata Memorial Centre under

More information

Hazards of Cytotoxic Drugs

Hazards of Cytotoxic Drugs 38 H Y G E I A HYGEIA Vol.1, No.1 March-Aug, 09 Hazards of Cytotoxic Drugs 1 2 Kiron SS, Saritha M 1 Academy of Pharmaceutical Sciences, Medical College, Pariyaram, Kannur, Kerala. 2 Crescent College of

More information

Antiemetic Guidelines for Adult Patients Receiving Chemotherapy and Radiotherapy

Antiemetic Guidelines for Adult Patients Receiving Chemotherapy and Radiotherapy Antiemetic Guidelines f Adult Patients Receiving Chemotherapy and Radiotherapy Produced by Pinkie Chambers and Susanna Daniels University College Hospital NHS Foundation Trust November 2010 (Review date

More information

Chemotherapy Drugs: How They Work

Chemotherapy Drugs: How They Work Chemotherapy Drugs: How They Work Chemotherapy is the use of any drug (such as aspirin or penicillin) to treat any disease. But to most people, chemotherapy refers to drugs used for cancer treatment. It

More information

Cancer and Fertility. Joanne Frankel Kelvin, MSN, RN, AOCN Clinical Nurse Specialist Memorial Sloan-Kettering Cancer Center

Cancer and Fertility. Joanne Frankel Kelvin, MSN, RN, AOCN Clinical Nurse Specialist Memorial Sloan-Kettering Cancer Center Cancer and Fertility Joanne Frankel Kelvin, MSN, RN, AOCN Clinical Nurse Specialist Memorial Sloan-Kettering Cancer Center Advances in cancer treatment have led to improvements in survival Survival rates

More information

Inspira (Vineland/Woobury) Open Clinical Trials as of December 16, 2015

Inspira (Vineland/Woobury) Open Clinical Trials as of December 16, 2015 Inspira (Vineland/Woobury) Open Clinical Trials as of December 16, 2015 Advanced Refractory Solid Tumors or Lymphomas ECOG-ACRIN EAY131 (NCI CIRB) Targeted Therapy Directed by Genetic Testing in Treating

More information

BreastCancerTrials.org History Form: Completed Treatment for Breast Cancer ABOUT ME

BreastCancerTrials.org History Form: Completed Treatment for Breast Cancer ABOUT ME BreastCancerTrials.org History Form: Completed Treatment for Breast Cancer This form is for patients with DCIS or early stage invasive cancer who are: On hormone therapy after breast cancer surgery Or

More information

Treating Patients with Hormone Receptor Positive, HER2 Positive Operable or Locally Advanced Breast Cancer

Treating Patients with Hormone Receptor Positive, HER2 Positive Operable or Locally Advanced Breast Cancer Breast Studies Adjuvant therapy after surgery Her 2 positive Breast Cancer B 52 Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients with Hormone

More information

BreastCancerTrials.org History Form: Metastatic Breast Cancer ABOUT ME

BreastCancerTrials.org History Form: Metastatic Breast Cancer ABOUT ME BreastCancerTrials.org History Form: Metastatic Breast Cancer This form is for patients with metastatic breast cancer who were: Were recently diagnosed with metastatic breast cancer (cancer that has spread

More information

Re: Formal Request for NCD Reconsideration- Tumor Antigen by ImmunoassayCA125 (40-17)

Re: Formal Request for NCD Reconsideration- Tumor Antigen by ImmunoassayCA125 (40-17) May 9, 2005 Coverage and Analysis Group Centers for Medicare and Medicaid Services 7500 Security Blvd. (Mailstop C1-09-06) Baltimore, MD 21244 Re: Formal Request for NCD Reconsideration- Tumor Antigen

More information

Breast Cancer. Breast Cancer Page 1

Breast Cancer. Breast Cancer Page 1 Breast Cancer Summary Breast cancers which are detected early are curable by local treatments. The initial surgery will give the most information about the cancer; such as size or whether the glands (or

More information

Classification of Hazardous Drugs by NIOSH

Classification of Hazardous Drugs by NIOSH Classification of Hazardous Drugs by NIOSH Thomas H. Connor, PhD Research Biologist National Institute for Occupational Safety and Health NIOSH Goals Protect workers from exposure to hazardous drugs Provide

More information

Review of the List of High-Cost Medicines used by the Dominican Republic s Protected Diseases Program and Planning of Purchases for 2015

Review of the List of High-Cost Medicines used by the Dominican Republic s Protected Diseases Program and Planning of Purchases for 2015 Review of the List of High-Cost Medicines used by the Dominican Republic s Protected Diseases Program and Planning of Purchases for 2015 July 2014 Review of the List of High-Cost Medicines Used by the

More information

Fertility and Women With Cancer

Fertility and Women With Cancer Fertility and Women With Cancer Although not everyone ends up having children, most people want to at least have the option. Cancer and treatment for cancer can sometimes make this harder or even take

More information

Male Health Issues. Survivorship Clinic

Male Health Issues. Survivorship Clinic Male Health Issues The effects of cancer therapy on male reproductive function depend on many factors, including the boy s age at the time of cancer therapy, the specific type and location of the cancer,

More information

APPENDIX: CHEMOTHERAPY SIDE EFFECT PROFILES

APPENDIX: CHEMOTHERAPY SIDE EFFECT PROFILES APPENDIX: CHEMOTHERAPY SIDE EFFECT PROFILES All chemotherapy drugs can cause side effects. No one can predict ahead of time what side effects you may experience or their severity. Some people experience

More information

Medicare Part D Plans Deliver Significant Savings on Innovative, Breakthrough Medicines

Medicare Part D Plans Deliver Significant Savings on Innovative, Breakthrough Medicines Medicare Part D Plans Deliver Significant Savings on Innovative, Breakthrough Medicines Survey Finds Private Sector Negotiations Provide Both Savings and Choice, Making Government Interference Unnecessary

More information

Development of the market of special care drugs

Development of the market of special care drugs Forecast Special Care Drugs Development of the market of special care drugs IGES Institut Berlin, April 6th 21 I G E S I n s t i t ut G m bh w w w. i ges.de Friedrichstraße 18 1117 Berlin Germany +49 3

More information

Treatment of Metastatic Breast Cancer: Endocrine Therapies. Robert W. Carlson, M.D. Professor of Medicine Stanford University

Treatment of Metastatic Breast Cancer: Endocrine Therapies. Robert W. Carlson, M.D. Professor of Medicine Stanford University Treatment of Metastatic Breast Cancer: Endocrine Therapies Robert W. Carlson, M.D. Professor of Medicine Stanford University MDACC Experience with FAC in Chemotherapy-Naive MBC Greenberg et al, J Clin

More information

Hormones & Hormone Antagonists Chapter 40 - Katzung

Hormones & Hormone Antagonists Chapter 40 - Katzung Hormones & Hormone Antagonists hapter 40 - Katzung Least toxic of anticancer drugs Highly selective Breast, endometrial, prostate cancers 5 ategories Androgens Progestins Antiandrogens Gonadotropin-releasing

More information

About chemotherapy for lung cancer

About chemotherapy for lung cancer About chemotherapy for lung cancer This information is about chemotherapy for lung cancer. There are sections on What is chemotherapy? Chemotherapy for small cell lung cancer Chemotherapy for non-small

More information

ANTICANCER DRUGS DR. R. JAMUNA RANI MD, PROFESSOR & HOD DEPT. OF PHARMACOLOGY

ANTICANCER DRUGS DR. R. JAMUNA RANI MD, PROFESSOR & HOD DEPT. OF PHARMACOLOGY ANTICANCER DRUGS DR. R. JAMUNA RANI MD, PROFESSOR & HOD DEPT. OF PHARMACOLOGY ANTICANCER DRUGS GENERAL PRINCIPLES IN CHEMOTHERAPY OF CANCER Bacterial metabolism differs markedly from that of host. While

More information

FREE ANSWER ONLINE FOR INSTANT RESULTS AT WWW.CANADIANHEALTHCARENETWORK.CA SEPTEMBER 2015. by Sanna Pellatt, BSc(Pharm) Learning objectives

FREE ANSWER ONLINE FOR INSTANT RESULTS AT WWW.CANADIANHEALTHCARENETWORK.CA SEPTEMBER 2015. by Sanna Pellatt, BSc(Pharm) Learning objectives FONT: HELVETICA NEUE 75 BOLD (MODIFIED) CYAN 50,YELLOW 100 MAGENTA 100 CYAN 100 Continuing Education THE NATIONAL CONTINUING EDUCATION PROGRAM FOR PHARMACY TECHNICIANS 1.25 CEUs FREE ANSWER ONLINE FOR

More information

Drugs covered under Medicare Part B or Part D

Drugs covered under Medicare Part B or Part D LABEL_NAME GENERIC_NAME MESSAGE GEMZAR INJ 1 GM GEMCITABINE HCL FOR INJ 1 GM ALIMTA INJ 500MG PEMETREXED DISODIUM FOR IV SOLN 500 MG (BASE EQUIV) FUNGIZONE INJ 50MG AMPHOTERICIN B FOR INJ 50 MG KYTRIL

More information

How Breast Cancer Treatment affects Massage Therapy

How Breast Cancer Treatment affects Massage Therapy How Breast Cancer Treatment affects Massage Therapy A Webinar with Tracy Walton, MS, LMT Part 4 of the More about Cancer Care and Massage Webinar Series 11 Background Tracy Walton Author Educator Researcher

More information

I will be having surgery and radiation treatment for breast cancer. Do I need drug treatment too?

I will be having surgery and radiation treatment for breast cancer. Do I need drug treatment too? What is node-positive breast cancer? Node-positive breast cancer means that cancer cells from the tumour in the breast have been found in the lymph nodes (sometimes called glands ) in the armpit area.

More information

Cancer patients waiting for potentially live-saving treatments in UK

Cancer patients waiting for potentially live-saving treatments in UK Cancer patients waiting for potentially live-saving treatments in UK 29 May 2005 UK patients are waiting too long for new treatments, according to a 'Dossier of Delay' compiled by information charity CancerBACUP.

More information

a nonprofit organization Cancer & Fertility Fast Facts for Oncology Professionals information support hope

a nonprofit organization Cancer & Fertility Fast Facts for Oncology Professionals information support hope a nonprofit organization Cancer & Fertility Fast Facts for Oncology Professionals information support hope table of contents introduction 1 male patients risks 2 options 2 female patients risks 6 options

More information

Breast Clinical Trials ADJUVANT, HER2+ BRE- 186 (Cohort A & B closed) Phase II Therapeutic Eribulin provided

Breast Clinical Trials ADJUVANT, HER2+ BRE- 186 (Cohort A & B closed) Phase II Therapeutic Eribulin provided FOR MORE ABOUT OR TO REFER A PATIENT TO ANY OF OUR CLINICAL TRIALS, PLEASE CONTACT THE OHC RESEARCH DEPARTMENT AT 1.800.710.4678. Breast Clinical Trials ADJUVANT, HER2+ BRE- 186 (Cohort A & B closed) Eribulin

More information

Second Cancers in Adults

Second Cancers in Adults Second Cancers in Adults This document focuses on second cancers in adults. For information about second cancers after treatment of childhood cancers, see our document Children Diagnosed With Cancer: Late

More information

CHEMOTHERAPY PROTOCOLS V10.1

CHEMOTHERAPY PROTOCOLS V10.1 CHEMOTHERAPY PROTOCOLS V10.1 Issue Date: 10 th July 2014 Page 1 of 42 Filename: MCHACPROTO Issue No: 10.1 CCC Chemotherapy Protocols Haematological Malignancies... 3 Hodgkins disease...3 Non-Hodgkins Lymphoma...5

More information

Prior Authorization Criteria

Prior Authorization Criteria Prior Authorization Criteria Adalimumab Based on the review of medical literature Adalimumab Injection is considered appropriate treatment for those A. A documented diagnosis of moderate to severe active

More information

Cancer Care Quality Program. Treatment Pathways

Cancer Care Quality Program. Treatment Pathways Cancer Care Quality Program Treatment Pathways REVISED: UPDATES EFFECTIVE DECEMBER 1, 2015 1 TABLE OF CONTENTS Contents CANCER CARE QUALITY PROGRAM 3 BLADDER CANCER PATHWAYS 4 BREAST CANCER PATHWAYS 5

More information

Cancer Drug Toxicities and Anaesthesia

Cancer Drug Toxicities and Anaesthesia Cancer Drug Toxicities and Anaesthesia 71 Cancer Drug Toxicities and Anaesthesia PAUL DE SOUZA, BSc (Med), MBBS, FRACP, MPH Senior Staff Specialist in Medical Oncology, St George Hospital, Sydney Dr de

More information

NICE DSU TECHNICAL SUPPORT DOCUMENT 14: SURVIVAL ANALYSIS FOR ECONOMIC EVALUATIONS ALONGSIDE CLINICAL TRIALS - EXTRAPOLATION WITH PATIENT-LEVEL DATA

NICE DSU TECHNICAL SUPPORT DOCUMENT 14: SURVIVAL ANALYSIS FOR ECONOMIC EVALUATIONS ALONGSIDE CLINICAL TRIALS - EXTRAPOLATION WITH PATIENT-LEVEL DATA NICE DSU TECHNICAL SUPPORT DOCUMENT 14: SURVIVAL ANALYSIS FOR ECONOMIC EVALUATIONS ALONGSIDE CLINICAL TRIALS - EXTRAPOLATION WITH PATIENT-LEVEL DATA REPORT BY THE DECISION SUPPORT UNIT June 2011 (last

More information

Knee Pain in Patients With Cancer After Chemotherapy, Radiotherapy, and Bone Marrow Transplantation

Knee Pain in Patients With Cancer After Chemotherapy, Radiotherapy, and Bone Marrow Transplantation Knee Pain in Patients With Cancer After Chemotherapy, Radiotherapy, and Bone Marrow Transplantation Eileen Chen, MD; Sajiv Sethi, BS; Adrienne Lee, BS; Anil Sethi, MD; Rahul Vaidya, MD abstract Full article

More information

HISTORY OF DEVELOPMENT CURRENT INDICATORS DEVELOPMENT PROSPECTS

HISTORY OF DEVELOPMENT CURRENT INDICATORS DEVELOPMENT PROSPECTS HISTORY OF DEVELOPMENT CURRENT INDICATORS DEVELOPMENT PROSPECTS 1. COMPANY DESCRIPTION Biocad is a Russian full cycle biotechnological company. It deals with development, manufacture and promotion of original

More information

BREAST CANCER WHAT HAPPENS AFTER SURGERY?

BREAST CANCER WHAT HAPPENS AFTER SURGERY? BREAST CANCER WHAT HAPPENS AFTER SURGERY? Contents: Planning further treatment Medical management of breast cancer Support and follow up Questions to ask your surgeon or oncologist Planning further treatment

More information

Hormonal therapy for advanced prostate cancer

Hormonal therapy for advanced prostate cancer Hormonal therapy for advanced prostate cancer This information is an extract from the booklet Understanding advanced (metastatic) prostate cancer. You may find the full booklet helpful. We can send you

More information

Second Cancers Caused by Cancer Treatment

Second Cancers Caused by Cancer Treatment Second Cancers Caused by Cancer Treatment Advances in radiation therapy and chemotherapy have increased the chances of survival for many people with cancer today. People with cancer are often living longer,

More information

Basics of Systemic Anticancer Therapy Prescribing and Verification

Basics of Systemic Anticancer Therapy Prescribing and Verification CHAPTER 2 Basics of Systemic Anticancer Therapy Prescribing and Verification Trinh Pham Joan Rivington Learning Objectives Upon completion of the chapter, the reader will be able to: 1. Write clear and

More information

How do fertility drugs work?

How do fertility drugs work? How do fertility drugs work? Under normal circumstances, ovulation occurs once a month when a ripened egg which is ready to be fertilised is released from the ovaries. For couples who are trying to conceive,

More information

National Cancer Drugs Fund List (Updated 13 February 2014)

National Cancer Drugs Fund List (Updated 13 February 2014) National Cancer Drugs Fund List (Updated 13 February 2014) DRUG Abiraterone Aflibercept Axitinib Bendamustine NCDF APPROVED CRITERIA The treatment of metastatic castration resistant prostate cancer where

More information

2014-06-10 Approved Bendamustine - Treatment of relapsed low grade NHL in patients unable to receive standard therapy 2014-05-

2014-06-10 Approved Bendamustine - Treatment of relapsed low grade NHL in patients unable to receive standard therapy 2014-05- Sub. Sub. Status -06-16 Approved Lenalidomide - 2nd line treatment of multiple myeloma in patients who have contraindications to the use of bortezomib -06-16 Approved Lenalidomide - 2nd line treatment

More information

Florida Breast Health Specialists Hormone Therapy Information and Questions to Ask Your Doctor

Florida Breast Health Specialists Hormone Therapy Information and Questions to Ask Your Doctor What is Hormone Therapy? Hormonal therapy medicines are whole-body (systemic) treatment for hormone-receptorpositive breast cancers. Hormone receptors are like ears on breast cells that listen to signals

More information

Cancer Chemotherapy and Pregnancy

Cancer Chemotherapy and Pregnancy SOGC CLINICAL PRACTICE GUIDELINE No. 288, March 2013 Cancer Chemotherapy and Pregnancy This clinical practice guideline has been prepared by the Chemotherapy During Pregnancy Working Group and approved

More information

Blend me in: Privacy-Preserving Input Generalization for Personalized Online Services

Blend me in: Privacy-Preserving Input Generalization for Personalized Online Services Blend me in: Privacy-Preserving Input Generalization for Personalized Online Services Alegria Baquero Institute for Software Research University of California, Irvine abaquero@ics.uci.edu Allan M. Schiffman

More information

Carcinoma of the vagina is a relatively uncommon disease, affecting only about 2,000 women in

Carcinoma of the vagina is a relatively uncommon disease, affecting only about 2,000 women in EVERYONE S GUIDE FOR CANCER THERAPY Malin Dollinger, MD, Ernest H. Rosenbaum, MD, Margaret Tempero, MD, and Sean Mulvihill, MD 4 th Edition, 2001 Vagina Jeffrey L. Stern, MD Carcinoma of the vagina is

More information

Index of compounds with data indicating they either cross or do not cross the bbb (or are found in CSF).

Index of compounds with data indicating they either cross or do not cross the bbb (or are found in CSF). Index of compounds with data indicating they either cross or do not cross the bbb (or are found in CSF). As described in the preceding review, there are several important issues when considering a chemotherapeutic

More information

Medical Surgical Nursing (Elsevier)

Medical Surgical Nursing (Elsevier) 1 of 6 I. The Musculoskeletal System Medical Surgical Nursing (Elsevier) 1. Med/Surg: Musculoskeletal System: The Comprehensive Health History 2. Med/Surg: Musculoskeletal System: A Nursing Approach to

More information

BRAIN TUMOUR RESEARCH FUNDING FLOWS

BRAIN TUMOUR RESEARCH FUNDING FLOWS BRAIN TUMOUR RESEARCH FUNDING FLOWS Ellen Harries, Iona Joy v London, April 2013 (updated) CONTENTS 1 Research brief and headline findings 2 Research funding for cancer 3 Brain tumour funding compared

More information

Objectives PREVENTION AND TREATMENT OF CINV & VTE IN ONCOLOGY PATIENTS. Case 1. Case 1. Case 2 2/1/2015

Objectives PREVENTION AND TREATMENT OF CINV & VTE IN ONCOLOGY PATIENTS. Case 1. Case 1. Case 2 2/1/2015 Objectives PREVENTION AND TREATMENT OF CINV & VTE IN ONCOLOGY PATIENTS Jennifer Gallanger, Pharm.D. Jennifer Kubert, Pharm.D. Pharmacy Practice Residents Providence Alaska Medical Center Discuss the pathophysiology

More information

Metastatic Breast Cancer - Pipeline Review, Q1 2011

Metastatic Breast Cancer - Pipeline Review, Q1 2011 Brochure More information from http://www.researchandmarkets.com/reports/1524592/ Metastatic Breast Cancer - Pipeline Review, Q1 2011 Description: Metastatic Breast Cancer - Pipeline Review, Q1 2011 Summary

More information

Everolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer

Everolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer LONDON CANCER NEWS DRUGS GROUP RAPID REVIEW Everolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer Everolimus plus exemestane for second-line

More information

J Clin Oncol 27:6243-6250. 2009 by American Society of Clinical Oncology

J Clin Oncol 27:6243-6250. 2009 by American Society of Clinical Oncology VOLUME 27 NUMBER 36 DECEMBER 20 2009 JOURNAL OF CLINICAL ONCOLOGY R E V I E W A R T I C L E Ultimate Fate of Oncology Drugs Approved by the US Food and Drug Administration Without a Randomized Trial Apostolia-Maria

More information

Understanding How Existing and Emerging MS Therapies Work

Understanding How Existing and Emerging MS Therapies Work Understanding How Existing and Emerging MS Therapies Work This is a promising and hopeful time in the field of multiple sclerosis (MS). Many new and different therapies are nearing the final stages of

More information

Menopause: should I take HRT?

Menopause: should I take HRT? Patient information from the BMJ Group Menopause: should I take HRT? The menopause is when your periods stop for good. It isn't an illness. It's a normal part of every woman's life. But sometimes it causes

More information

Highlights. www.lls.org Information Specialist: 800.955.4572. Psychological development. This publication was supported by a grant from

Highlights. www.lls.org Information Specialist: 800.955.4572. Psychological development. This publication was supported by a grant from Long-Term and Late Effects of Treatment for Childhood Leukemia or Lymphoma Facts No. 15 in a series providing the latest information for patients, caregivers and healthcare professionals www.lls.org Information

More information

Shira Miller, M.D. Los Angeles, CA 310-734-8864 www.shiramillermd.com. The Compounding Pharmacy of Beverly Hills Beverly Hills Public Library

Shira Miller, M.D. Los Angeles, CA 310-734-8864 www.shiramillermd.com. The Compounding Pharmacy of Beverly Hills Beverly Hills Public Library Shira Miller, M.D. Los Angeles, CA 310-734-8864 The Compounding Pharmacy of Beverly Hills Beverly Hills Public Library 2 Outline What is hormone therapy? Why would healthy men and women need to think about

More information

Lymphomas after organ transplantation

Lymphomas after organ transplantation Produced 21.03.2011 Revision due 21.03.2011 Lymphomas after organ transplantation People who have undergone an organ transplant are more at risk of developing lymphoma known as post-transplant lymphoproliferative

More information

Pediatric Oncology for Otolaryngologists

Pediatric Oncology for Otolaryngologists Pediatric Oncology for Otolaryngologists Frederick S. Huang, M.D. Division of Hematology/Oncology Department of Pediatrics The University of Texas Medical Branch Grand Rounds Presentation to Department

More information

Phase III trials in oncology

Phase III trials in oncology Phase III trials in oncology Setting standards of care? Siegfried Seeber and Ada H Braun* Survival data from phase III trials can be very misleading because patients are not offered the best follow-up

More information

Chapter 7: Lung Cancer

Chapter 7: Lung Cancer Chapter 7: Lung Cancer Contents Chapter 7: Lung Cancer... 1 Small Cell... 2 Good PS + Limited stage... 2 Cisplatin/etoposide... 2 Concurrent chemotherapy + XRT... 2 Good / Intermediate PS... 2 Carboplatin

More information

Cytotoxic Drug Contamination in Hospital and Municipal Wastewater and Its Transfer to Surface Water

Cytotoxic Drug Contamination in Hospital and Municipal Wastewater and Its Transfer to Surface Water Cytotoxic Drug Contamination in Hospital and Municipal Wastewater and Its Transfer to Surface Water Pharma-Cycle Inc. Theresa L. O'Keefe, Ph.D. Chief Scientific Officer September 21, 2011 Introduction

More information

Recruitment Start date: April 2010 End date: Recruitment will continue until enrolment is fully completed

Recruitment Start date: April 2010 End date: Recruitment will continue until enrolment is fully completed Apitope study The study drug (ATX-MS-1467) is a new investigational drug being tested as a potential treatment for relapsing forms of multiple sclerosis (RMS). The term investigational drug means it has

More information

43,303,919 paid out in critical illness claims in the first six months of 2012*

43,303,919 paid out in critical illness claims in the first six months of 2012* Critical Illness Claims Report 43,303,919 out in critical illness claims in the first six months of 2012* 60 % Cancer 16 % Heart Attack 10 % Other 3 % Benign Brain Tumour 5 % Multiple Sclerosis 6 % Stroke

More information

Cytotoxic Therapy in Metastatic Breast Cancer

Cytotoxic Therapy in Metastatic Breast Cancer Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Cytotoxic Therapy in Metastatic Breast Cancer Cytotoxic Therapy in Metastatic Breast Cancer Version 2002: von Minckwitz Versions

More information

R E X C A N C E R C E N T E R. Annual Report 2012. Rex Cancer Care Committee 2012 On behalf of the Rex Cancer Center & Rex Health Care

R E X C A N C E R C E N T E R. Annual Report 2012. Rex Cancer Care Committee 2012 On behalf of the Rex Cancer Center & Rex Health Care R E X C A N C E R C E N T E R Annual Report 2012 Rex Cancer Care Committee 2012 On behalf of the Rex Cancer Center & Rex Health Care An American College of Surgeons Commission on Cancer Accredited Comprehensive

More information

Dr. Friedman s Guide to Estrogen Replacement

Dr. Friedman s Guide to Estrogen Replacement Dr. Friedman s Guide to Estrogen Replacement There are risks and benefits with all medicines and estrogen replacement is no exception. In fact, estrogen replacement is one of the most controversial topics

More information

Fertility Preservation in Women with Cancer. Objectives. Patient #1 10/24/2011. The audience will understand: How cancer therapy affects fertility.

Fertility Preservation in Women with Cancer. Objectives. Patient #1 10/24/2011. The audience will understand: How cancer therapy affects fertility. Fertility Preservation in Women with Cancer Leslie R. DeMars Dartmouth-Hitchcock Medical Center Objectives The audience will understand: How cancer therapy affects fertility. Who should be considered for

More information

Chemotherapy Order Assessment and Review

Chemotherapy Order Assessment and Review Chemotherapy Order Assessment and Review Contents Introduction... 2 Step 1: Verify Patient Information... 2 Step 2: Confirm Protocol Matches Clinical Indication and Eligibility for Treatment... 2 Step

More information

The Impact of New Orphanet Drug Approvals on Premature Mortality

The Impact of New Orphanet Drug Approvals on Premature Mortality The impact of new (orphan) drug approvals on premature mortality from rare diseases in the U.S. and France, 1999-2007 Frank R. Lichtenberg Columbia University and National Bureau of Economic Research frank.lichtenberg@columbia.edu

More information